Naringin does not alter caffeine pharmacokinetics, energy expenditure, or cardiovascular haemodynamics in humans following caffeine consumption. 2006

Tasha L P Ballard, and Fathi T Halaweish, and Cheryl L Stevermer, and Puja Agrawal, and Matthew D Vukovich
South Dakota Health Promotion and Research Program, Applied Physiology Laboratory, South Dakota State University, Brookings 57007, USA.

1. Naringin, a grapefruit constituent interacts with many medications including caffeine, a popular weight loss supplement. The purpose of the current study was to identify changes in caffeine pharmacokinetics, resting energy expenditure (REE), oxygen consumption (VO(2)) and respiratory exchange ratio (RER) after an acute dosage of caffeine and naringin. 2. Using a double-blinded, counterbalanced design, REE, VO(2), and RER were measured before and systematically for 8 h after a single dosage of caffeine (CAF, 200 mg) with and without naringin (100 mg (CN100) or 200 mg (CN200)) in 10 apparently healthy individuals. A standardized meal was provided following 240-minute measurements (400 kcals; 35 g carbohydrate; 27 g protein; 7 g fat). 3. Caffeine, CN100, CN200 did not alter VO(2) or VO(2) area under the curve (137 301 +/- 8318, 139 729 +/- 9300, 134 297 +/- 8318, mL/480 min). Resting energy expenditure (k/cals) was 10.0 +/- 1.4% higher with CAF versus CN200 (6.0 +/- 1.4%) and CN100 (6 +/- 1.5%) at 240 min (P = 0.07) which was then negated following a standardized meal. Percent change in RER from pre to 240 min and pre to 480 min was not different between the CAF, CN100, or CN200 (-0.2 +/- 1.7%, 1.7 +/- 1.7%, -2.8 +/- 1.9%). 4. Although caffeine alone suggests a trend of increased REE, the results of the present study indicate that concurrent consumption of caffeine with naringin in acute dosages does not affect RER, VO(2), and prevents the increase of REE in adult humans. The results suggest that the interaction of grapefruit juice and caffeine may be due to constituents of grapefruit juice other than naringin or in addition to naringin.

UI MeSH Term Description Entries
D008297 Male Males
D010101 Oxygen Consumption The rate at which oxygen is used by a tissue; microliters of oxygen STPD used per milligram of tissue per hour; the rate at which oxygen enters the blood from alveolar gas, equal in the steady state to the consumption of oxygen by tissue metabolism throughout the body. (Stedman, 25th ed, p346) Consumption, Oxygen,Consumptions, Oxygen,Oxygen Consumptions
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002110 Caffeine A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine's most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes SMOOTH MUSCLE, stimulates CARDIAC MUSCLE, stimulates DIURESIS, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide PHOSPHODIESTERASES, antagonism of ADENOSINE RECEPTORS, and modulation of intracellular calcium handling. 1,3,7-Trimethylxanthine,Caffedrine,Coffeinum N,Coffeinum Purrum,Dexitac,Durvitan,No Doz,Percoffedrinol N,Percutaféine,Quick-Pep,Vivarin,Quick Pep,QuickPep
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004734 Energy Metabolism The chemical reactions involved in the production and utilization of various forms of energy in cells. Bioenergetics,Energy Expenditure,Bioenergetic,Energy Expenditures,Energy Metabolisms,Expenditure, Energy,Expenditures, Energy,Metabolism, Energy,Metabolisms, Energy
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic

Related Publications

Tasha L P Ballard, and Fathi T Halaweish, and Cheryl L Stevermer, and Puja Agrawal, and Matthew D Vukovich
October 1987, Journal of hepatology,
Tasha L P Ballard, and Fathi T Halaweish, and Cheryl L Stevermer, and Puja Agrawal, and Matthew D Vukovich
February 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,
Tasha L P Ballard, and Fathi T Halaweish, and Cheryl L Stevermer, and Puja Agrawal, and Matthew D Vukovich
August 1992, Journal of clinical psychopharmacology,
Tasha L P Ballard, and Fathi T Halaweish, and Cheryl L Stevermer, and Puja Agrawal, and Matthew D Vukovich
January 2015, PloS one,
Tasha L P Ballard, and Fathi T Halaweish, and Cheryl L Stevermer, and Puja Agrawal, and Matthew D Vukovich
January 1993, European journal of clinical pharmacology,
Tasha L P Ballard, and Fathi T Halaweish, and Cheryl L Stevermer, and Puja Agrawal, and Matthew D Vukovich
February 1998, European journal of clinical pharmacology,
Tasha L P Ballard, and Fathi T Halaweish, and Cheryl L Stevermer, and Puja Agrawal, and Matthew D Vukovich
February 2004, Psychopharmacology,
Tasha L P Ballard, and Fathi T Halaweish, and Cheryl L Stevermer, and Puja Agrawal, and Matthew D Vukovich
January 2016, International journal of sports medicine,
Tasha L P Ballard, and Fathi T Halaweish, and Cheryl L Stevermer, and Puja Agrawal, and Matthew D Vukovich
April 2003, Therapeutic drug monitoring,
Tasha L P Ballard, and Fathi T Halaweish, and Cheryl L Stevermer, and Puja Agrawal, and Matthew D Vukovich
November 1995, International journal of clinical pharmacology and therapeutics,
Copied contents to your clipboard!